Search

Your search keyword '"Conconi, Annarita"' showing total 315 results

Search Constraints

Start Over You searched for: Author "Conconi, Annarita" Remove constraint Author: "Conconi, Annarita"
315 results on '"Conconi, Annarita"'

Search Results

1. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial

2. IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma

4. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study

5. IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma

6. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

8. Impact of immunochemotherapy with R‐bendamustine or R‐CHOP for treatment naïve advanced‐stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi

9. A MALT lymphoma prognostic index

11. Revised MALT‐IPI: A new predictive model that identifies high‐risk patients with extranodal marginal zone lymphoma

12. Revised MALT-IPI: A new predictive model that identifies high-risk patients with extranodal marginal zone lymphoma

13. Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL)

14. Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

15. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group

17. Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi

22. ABCL-135: RE-MIND: A Comparison of Tafasitamab (MOR208) + Lenalidomide (L-MIND) Versus Lenalidomide Monotherapy (Real-World Data) in Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

24. Revised-MALT-IPI: A New Predictive Model That Identifies High-Risk Patients with Extranodal Marginal Zone Lymphoma (EMZL)

30. Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals

35. Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience

39. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue

42. Late relapse in patients with diffuse large B‐cell lymphoma: impact of rituximab on their incidence and outcome

43. Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice

44. Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients

45. Molecular follow-up in gastric mucosa–associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial

48. High‐dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL‐GITMO

50. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with “standard” immunochemotherapy: A large retrospective study from 4 institutions

Catalog

Books, media, physical & digital resources